Incyte and Genmab Collaborate on Colorectal Cancer Trial
The companies will evaluate Incyte’s investigational KRAS G12D inhibitor INCB161734 with Genmab’s investigational antibody petosemtamab in metastatic colorectal cancer.
Story updates
11:00:58 AM UTC
SquawkNews
Incyte announced a collaboration with Genmab to evaluate INCB161734 plus petosemtamab and standard chemotherapy in a Phase 1/2 first-line study for KRAS G12D-mutated metastatic colorectal cancer. Genmab will run the study; Incyte will co-fund and supply INCB161734.Material DetailsContext by AI Anal…
11:01:34 AM UTC
SquawkNews
Genmab will run a Phase 1/2 study of petosemtamab with Incyte’s KRAS G12D inhibitor INCB161734 plus standard chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer; Incyte will co-fund and supply its drug.Material DetailsContext by AI AnalystThis is an early-stage R&D expansion a…